- Physiomics
- 04 November 2024 12:11:45
Source: Sharecast
The AIM-traded firm said Dr Davies, who joined this week, was bringing over 20 years of experience in drug development, including significant roles at major pharmaceutical companies like AstraZeneca and within biopharma support services.
His expertise spanned computational biology, data informatics, and various phases of drug discovery, providing a strong foundation for his new leadership role.
In his position, Dr Davies would oversee Physiomics’ modelling, simulation and data science services, playing a central role in the company’s strategic direction alongside the chief executive and the board.
His primary focus would be on driving growth and operational efficiency within the service line, while collaborating with the head of business development to expand market reach and accelerate new contract acquisitions.
Additionally, he would manage the technical team to ensure the timely and quality delivery of consultancy projects.
Dr Davies holds a PhD in biological sciences from the University of Warwick and a B.Sc. in biochemistry from the University of Bath.
“We are delighted to welcome Mark to our team,” said chief executive officer Dr Peter Sargent.
“We feel that his unique mix of technical and commercial experience spanning across modelling and simulation, data science and drug development, he will be a great addition to the company.”
At 0902 GMT, shares in Physiomics were down 0.86% at 0.64p.
Reporting by Josh White for Sharecast.com.